Recommended Adult Immunization Schedule--United States - 2015 by South Carolina Department of Health and Environmental Control
VACCINE  AGE GROUP  19-21 years 22-26 years 27-49 years 50-59 years 60-64 years ≥ 65 years
Influenza*,2
Tetanus, diphtheria, pertussis (Td/Tdap)*,3
Varicella*,4
Human papillomavirus (HPV) Female*,5
Human papillomavirus (HPV) Male*,5
Zoster6
Measles, mumps, rubella (MMR)*,7
Pneumococcal 13-valent conjugate (PCV13)*,8
Pneumococcal polysaccharide (PPSV23)8
Meningococcal*,9
Hepatitis A*,10
Hepatitis B*,11
Haemophilus influenzae type b (Hib)*,12
*Covered by the Vaccine Injury Compensation Program
3 doses
1 or 3 doses
2 doses
1 or more doses
1 dose1 or 2 doses
1 or 2 doses
1 dose
3 doses
2 doses
Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs
1 dose annually
For all persons in this category who 
meet the age requirements and who 
lack documentation of vaccination or 
have no evidence of previous infection; 
zoster vaccine recommended regardless 
of prior episode of zoster
Recommended if some other risk 
factor is present (e.g., on the basis of 
medical, occupational, lifestyle, or other 
indication)
No recommendation
Recommended Adult Immunization Schedule—United States - 2015
Note: These recommendations must be read with the footnotes that follow
containing number of doses, intervals between doses, and other important information.
Figure 1. Recommended adult immunization schedule, by vaccine and age group1
report are available at www.vaers.hhs.gov or by telephone, 800-822-7967.
www.hrsa.gov/vaccinecompensation
claim for vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.
Additional information about the vaccines in this schedule, extent of available data, and contraindications for vaccination is also available at  
www.cdc.gov/vaccines or from the CDC-INFO Contact Center at 800-CDC-INFO (800-232-4636) in English and Spanish, 8:00 a.m. - 8:00 p.m. Eastern Time, Monday - 
Friday, excluding holidays.
The recommendations in this schedule were approved by the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices 
(ACIP), the American Academy of Family Physicians (AAFP), the America College of Physicians (ACP), American College of Obstetricians and Gynecologists (ACOG) and 
American College of Nurse-Midwives (ACNM).
VACCINE  INDICATION  Pregnancy
Immuno-
compromising
conditions 
(excluding human 
virus [HIV]) 4,6,7,8,13
HIV infection
CD4+ T lymphocyte
count 4,6,7,8,13 Men who 
have sex 
with men 
(MSM)
Kidney failure, 
end-stage renal 
disease, receipt of 
hemodialysis
Heart disease,
chronic
lung disease,
chronic
alcoholism
Asplenia (including 
elective splenectomy 
and persistent 
complement component
8,12
Chronic 
liver 
disease Diabetes
Healthcare
personnel
< 200
cells/μL
≥ 200
cells/μL
Influenza*,2
Tetanus, diphtheria, pertussis (Td/Tdap)*,3
Varicella*,4
Human papillomavirus (HPV) Female*,5
Human papillomavirus (HPV) Male*,5
Zoster6
Measles, mumps, rubella (MMR)*,7
Pneumococcal 13-valent conjugate (PCV13)*,8 
Pneumococcal polysaccharide (PPSV23)8
Meningococcal*,9
Hepatitis A*,10
Hepatitis B*,11
Haemophilus influenzae type b (Hib)*,12
3 doses
1 or 3 doses
2 doses
1 or more doses
1 dose
1 or 2 doses
1 or 2 dosesContraindicated
1 doseContraindicated
3 doses through age 21 yrs3 doses through age 26 yrs
3 doses through age 26 yrs3 doses through age 26 yrs
2 dosesContraindicated
Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs
1 does IIV or  
LAIV annually1 dose IIV annually
1 dose IIV or 
LAIV annually
1 dose Tdap each 
pregnancy
1 dose IIV annually
Figure 2. Vaccines that might be indicated for adults based on medical and other indications1
post-HSCT  
recipients only
For all persons in this category who meet the age 
requirements and who lack documentation of vaccination 
or have no evidence of previous infection; zoster vaccine 
recommended regardless of prior episode of zoster  
Recommended if some other risk factor is present 
(e.g., on the basis of medical, occupational, lifestyle, or 
other indications) 
No recommendation
*Covered by the Vaccine Injury Compensation Program 
3 doses
1-time dose
These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly 
recommended for adults ages 19 years and older, as of February 1, 2015. For all vaccines being recommended on the Adult Immunization Schedule: a vaccine series 
does not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be used whenever any components of 
the combination are indicated and when the vaccine’s other components are not contraindicated. For detailed recommendations on all vaccines, including those 
used primarily for travelers or that are issued during the year, consult the manufacturers’ package inserts and the complete statements from the Advisory 
Committee on Immunization Practices (www.cdc.gov/vaccines/hcp/acip-recs/index.html). Use of trade names and commercial sources is for identication only 
and does not imply endorsement by the U.S. Department of Health and Human Services.
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For more information visit:
www.scdhec.gov/scimmunize
Recommended Adult Immunization Schedule—United States - 2015
Note: These recommendations must be read with the footnotes that follow containing number of 
doses, intervals between doses, and other important information. 
For more information visit www.scdhec.gov/scimmunize.
Footnotes — Recommended Immunization Schedule for Adults Aged 19 Years and Older: United States, 2015
1. Additional information
•	 Additional guidance for the use of the vaccines described in this supplement is 
available at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
•	 Information on vaccination recommendations when vaccination status is 
unknown and other general immunization information can be found in the 
General Recommendations on Immunization at  
www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.
•	 Information on travel vaccine requirements and recommendations (e.g., for 
hepatitis A and B, meningococcal, and other vaccines) is available at  
wwwnc.cdc.gov/travel/destinations/list.
•	 Additional information and resources regarding vaccination of pregnant 
women can be found at www.cdc.gov/vaccines/adults/rec-vac/pregnant.html.
2. Influenza vaccination
•	 Annual vaccination against influenza is recommended for all persons aged 6 
months or older.
•	 Persons aged 6 months or older, including pregnant women and persons with 
hives-only allergy to eggs can receive the inactivated influenza vaccine (IIV). An 
age-appropriate IIV formulation should be used.
•	 Adults aged 18 years or older can receive the recombinant influenza vaccine 
(RIV) (FluBlok). RIV does not contain any egg protein and can be given to age-
appropriate persons with egg allergy of any severity.
•	 Healthy, nonpregnant persons aged 2 to 49 years without high-risk medical 
conditions can receive either intranasally administered live, attenuated 
influenza vaccine (LAIV) (FluMist) or IIV.
•	 Health care personnel who care for severely immunocompromised persons 
who require care in a protected environment should receive IIV or RIV; health 
care personnel who receive LAIV should avoid providing care for severely 
immunosuppressed persons for 7 days after vaccination.
•	 The intramuscularly or intradermally administered IIV are options for adults 
aged 18 through 64 years.
•	 Adults aged 65 years or older can receive the standard-dose IIV or the high-
dose IIV (Fluzone High-Dose).
•	 A list of currently available influenza vaccines can be found at  
www.cdc.gov/flu/protect/vaccine/vaccines.htm.
3. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination
•	 Administer 1 dose of Tdap vaccine to pregnant women during each pregnancy 
(preferably during 27 to 36 weeks’ gestation) regardless of interval since prior Td 
or Tdap vaccination.
•	 Persons aged 11 years or older who have not received Tdap vaccine or for 
whom vaccine status is unknown should receive a dose of Tdap followed by 
tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter. 
Tdap can be administered regardless of interval since the most recent tetanus 
or diphtheria-toxoid containing vaccine.
•	 Adults with an unknown or incomplete history of completing a 3-dose primary 
vaccination series with Td-containing vaccines should begin or complete a 
primary vaccination series including a Tdap dose.
•	 For unvaccinated adults, administer the first 2 doses at least 4 weeks apart and 
the third dose 6 to 12 months after the second.
•	 For incompletely vaccinated (i.e., less than 3 doses) adults, administer 
remaining doses.
•	 Refer to the ACIP statement for recommendations for administering Td/Tdap as 
prophylaxis in wound management (see footnote 1).
4. Varicella vaccination
•	 All adults without evidence of immunity to varicella (as defined below) should 
receive 2 doses of single-antigen varicella vaccine or a second dose if they have 
received only 1 dose.
•	 Vaccination should be emphasized for those who have close contact with 
persons at high risk for severe disease (e.g., health care personnel and 
family contacts of persons with immunocompromising conditions) or are at 
high risk for exposure or transmission (e.g., teachers; child care employees; 
residents and staff members of institutional settings, including correctional 
institutions; college students; military personnel; adolescents and adults living 
in households with children; nonpregnant women of childbearing age; and 
international travelers).
•	 Pregnant women should be assessed for evidence of varicella immunity. 
Women who do not have evidence of immunity should receive the first dose 
of varicella vaccine upon completion or termination of pregnancy and before 
discharge from the health care facility. The second dose should be administered 
4 to 8 weeks after the first dose.
•	 Evidence of immunity to varicella in adults includes any of the following:
 — documentation of 2 doses of varicella vaccine at least 4 weeks apart;
 — U.S.-born before 1980, except health care personnel and pregnant women;
 — history of varicella based on diagnosis or verification of varicella disease by 
a health care provider;
 — history of herpes zoster based on diagnosis or verification of herpes zoster 
disease by a health care provider; or
 — laboratory evidence of immunity or laboratory confirmation of disease.
5. Human papillomavirus (HPV) vaccination
•	 Two vaccines are licensed for use in females, bivalent HPV vaccine (HPV2) and 
quadrivalent HPV vaccine (HPV4), and one HPV vaccine for use in males (HPV4).
•	 For females, either HPV4 or HPV2 is recommended in a 3-dose series for routine 
vaccination at age 11 or 12 years and for those aged 13 through 26 years, if not 
previously vaccinated.
•	 For males, HPV4 is recommended in a 3-dose series for routine vaccination at 
age 11 or 12 years and for those aged 13 through 21 years, if not previously 
vaccinated. Males aged 22 through 26 years may be vaccinated.
•	 HPV4 is recommended for men who have sex with men through age 26 years 
for those who did not get any or all doses when they were younger.
•	 Vaccination is recommended for immunocompromised persons (including 
those with HIV infection) through age 26 years for those who did not get any or 
all doses when they were younger.
•	 A complete series for either HPV4 or HPV2 consists of 3 doses. The second dose 
should be administered 4 to 8 weeks (minimum interval of 4 weeks) after the 
first dose; the third dose should be administered 24 weeks after the first dose 
and 16 weeks after the second dose (minimum interval of at least 12 weeks).
•	 HPV vaccines are not recommended for use in pregnant women. However, 
pregnancy testing is not needed before vaccination. If a woman is found to 
be pregnant after initiating the vaccination series, no intervention is needed; 
the remainder of the 3-dose series should be delayed until completion or 
termination of pregnancy.
6. Zoster vaccination
•	 A single dose of zoster vaccine is recommended for adults aged 60 years 
or older regardless of whether they report a prior episode of herpes zoster. 
Although the vaccine is licensed by the U.S. Food and Drug Administration for 
use among and can be administered to persons aged 50 years or older, ACIP 
recommends that vaccination begin at age 60 years.
•	 Persons aged 60 years or older with chronic medical conditions may be 
vaccinated unless their condition constitutes a contraindication, such as 
pregnancy or severe immunodeficiency.
7. Measles, mumps, rubella (MMR) vaccination
•	 Adults born before 1957 are generally considered immune to measles and 
mumps. All adults born in 1957 or later should have documentation of 1 or 
more doses of MMR vaccine unless they have a medical contraindication to 
the vaccine or laboratory evidence of immunity to each of the three diseases. 
Documentation of provider-diagnosed disease is not considered acceptable 
evidence of immunity for measles, mumps, or rubella.
Measles component:
•	 A routine second dose of MMR vaccine, administered a minimum of 28 days 
after the first dose, is recommended for adults who:
 — are students in postsecondary educational institutions,
 — work in a health care facility, or
 — plan to travel internationally.
•	 Persons who received inactivated (killed) measles vaccine or measles vaccine of 
unknown type during 1963–1967 should be revaccinated with 2 doses of MMR 
vaccine.
Mumps component:
•	 A routine second dose of MMR vaccine, administered a minimum of 28 days 
after the first dose, is recommended for adults who:
 — are students in a postsecondary educational institution,
 — work in a health care facility, or
 — plan to travel internationally.
•	 Persons vaccinated before 1979 with either killed mumps vaccine or mumps 
vaccine of unknown type who are at high risk for mumps infection (e.g., persons 
who are working in a health care facility) should be considered for revaccination 
with 2 doses of MMR vaccine.
Rubella component:
•	 For women of childbearing age, regardless of birth year, rubella immunity 
should be determined. If there is no evidence of immunity, women who are not 
pregnant should be vaccinated. Pregnant women who do not have evidence 
of immunity should receive MMR vaccine upon completion or termination of 
pregnancy and before discharge from the health care facility.
Health care personnel born before 1957:
•	 For unvaccinated health care personnel born before 1957 who lack laboratory 
evidence of measles, mumps, and/or rubella immunity or laboratory 
confirmation of disease, health care facilities should consider vaccinating 
personnel with 2 doses of MMR vaccine at the appropriate interval for measles 
and mumps or 1 dose of MMR vaccine for rubella.
8. Pneumococcal (13-valent pneumococcal conjugate vaccine [PCV13] 
and 23-valent pneumococcal polysaccharide vaccine [PPSV23]) 
vaccination
•	 General information
 — When indicated, only a single dose of PCV13 is recommended for adults.
 — No additional dose of PPSV23 is indicated for adults vaccinated with 
PPSV23 at or after age 65 years.
 — When both PCV13 and PPSV23 are indicated, PCV13 should be 
administered first; PCV13 and PPSV23 should not be administered during 
the same visit.
 — When indicated, PCV13 and PPSV23 should be administered to adults 
whose pneumococcal vaccination history is incomplete or unknown.
•	 Adults aged 65 years or older who
 — Have not received PCV13 or PPSV23: Administer PCV13 followed by PPSV23 
in 6 to 12 months.
 — Have not received PCV13 but have received a dose of PPSV23 at age 65 
years or older: Administer PCV13 at least 1 year after the dose of PPSV23 
received at age 65 years or older.
Footnotes—Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2015
(Continued on next page)
1. Additional information
•	 Additional guidance for the use of the vaccines described in this supplement is 
available at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
•	 Information on vaccination recommendations when vaccination status is 
unknown and other general immunization information can be found in the 
General Recommendations on Immunization at  
www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.
•	 Information on travel vaccine requirements and recommendations (e.g., for 
hepatitis A and B, meningococcal, and other vaccines) is available at  
wwwnc.cdc.gov/travel/destinations/list.
•	 Additional information and resources regarding vaccination of pregnant 
women can be found at www.cdc.gov/vaccines/adults/rec-vac/pregnant.html.
2. Influenza vaccination
•	 Annual vaccination against influenza is recommended for all persons aged 6 
months or older.
•	 Persons aged 6 months or older, including pregnant women and persons with 
hives-only allergy to eggs can receive the inactivated influenza vaccine (IIV). An 
age-appropriate IIV formulation should be used.
•	 Adults aged 18 years or older can receive the recombinant influenza vaccine 
(RIV) (FluBlok). RIV does not contain any egg protein and can be given to age-
appropriate persons with egg allergy of any severity.
•	 Healthy, nonpregnant persons aged 2 to 49 years without high-risk medical 
conditions can receive either intranasally administered live, attenuated 
influenza vaccine (LAIV) (FluMist) or IIV.
•	 Health care personnel who care for severely immunocompromised persons 
who require care in a protected environment should receive IIV or RIV; health 
care personnel who receive LAIV should avoid providing care for severely 
immunosuppressed persons for 7 days after vaccination.
•	 The intramuscularly or intradermally administered IIV are options for adults 
aged 18 through 64 years.
•	 Adults aged 65 years or older can receive the standard-dose IIV or the high-
dose IIV (Fluzone High-Dose).
•	 A list of currently available influenza vaccines can be found at  
www.cdc.gov/flu/protect/vaccine/vaccines.htm.
3. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination
•	 Administer 1 dose of Tdap vaccine to pregnant women during each pregnancy 
(preferably during 27 to 36 weeks’ gestation) regardless of interval since prior Td 
or Tdap vaccination.
•	 Persons aged 11 years or older who have not received Tdap vaccine or for 
whom vaccine status is unknown should receive a dose of Tdap followed by 
tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter. 
Tdap can be administered regardless of interval since the most recent tetanus 
or diphtheria-toxoid containing vaccine.
•	 Adults with an unknown or incomplete history of completing a 3-dose primary 
vaccination series with Td-containing vaccines should begin or complete a 
primary vaccination series including a Tdap dose.
•	 For unvaccinated adults, administer the first 2 doses at least 4 weeks apart and 
the third dose 6 to 12 months after the second.
•	 For incompletely vaccinated (i.e., less than 3 doses) adults, administer 
remaining doses.
•	 Refer to the ACIP statement for recommendations for administering Td/Tdap as 
prophylaxis in wound management (see footnote 1).
4. Varicella vaccination
•	 All adults without evidence of immunity to varicella (as defined below) should 
receive 2 doses of single-antigen varicella vaccine or a second dose if they have 
received only 1 dose.
•	 Vaccination should be emphasized for those who have close contact with 
persons at high risk for severe disease (e.g., health care personnel and 
family contacts of persons with immunocompromising conditions) or are at 
high risk for exposure or transmission (e.g., teachers; child care employees; 
residents and staff members of institutional settings, including correctional 
institutions; college students; military personnel; adolescents and adults living 
in households with children; nonpregnant women of childbearing age; and 
international travelers).
•	 Pregnant women should be assessed for evidence of varicella immunity. 
Women who do not have evidence of immunity should receive the first dose 
of varicella vaccine upon completion or termination of pregnancy and before 
discharge from the health care facility. The second dose should be administered 
4 to 8 weeks after the first dose.
•	 Evidence of immunity to varicella in adults includes any of the following:
 — documentation of 2 doses of varicella vaccine at least 4 weeks apart;
 — U.S.-born before 1980, except health care personnel and pregnant women;
 — history of varicella based on diagnosis or verification of varicella disease by 
a health care provider;
 — history of herpes zoster based on diagnosis or verification of herpes zoster 
disease by a health care provider; or
 — laboratory evidence of immunity or laboratory confirmation of disease.
5. Human papillomavirus (HPV) vaccination
•	 Two vaccines are licensed for use in females, bivalent HPV vaccine (HPV2) and 
quadrivalent HPV vaccine (HPV4), and one HPV vaccine for use in males (HPV4).
•	 For females, either HPV4 or HPV2 is recommended in a 3-dose series for routine 
vaccination at age 11 or 12 years and for those aged 13 through 26 years, if not 
previously vaccinated.
•	 For males, HPV4 is recommended in a 3-dose series for routine vaccination at 
age 11 or 12 years and for those aged 13 through 21 years, if not previously 
vaccinated. Males aged 22 through 26 years may be vaccinated.
•	 HPV4 is recommended for men who have sex with men through age 26 years 
for those who did not get any or all doses when they were younger.
•	 Vaccination is recommended for immunocompromised persons (including 
those with HIV infection) through age 26 years for those who did not get any or 
all doses when they were younger.
•	 A complete series for either HPV4 or HPV2 consists of 3 doses. The second dose 
should be administered 4 to 8 weeks (minimum interval of 4 weeks) after the 
first dose; the third dose should be administered 24 weeks after the first dose 
and 16 weeks after the second dose (minimum interval of at least 12 weeks).
•	 HPV vaccines are not recommended for use in pregnant women. However, 
pregnancy testing is not needed before vaccination. If a woman is found to 
be pregnant after initiating the vaccination series, no intervention is needed; 
the remainder of the 3-dose series should be delayed until completion or 
termination of pregnancy.
6. Zoster vaccination
•	 A single dose of zoster vaccine is recommended for adults aged 60 years 
or older regardless of whether they report a prior episode of herpes zoster. 
Although the vaccine is licensed by the U.S. Food and Drug Administration for 
use among and can be administered to persons aged 50 years or older, ACIP 
recommends that vaccination begin at age 60 years.
•	 Persons aged 60 years or older with chronic medical conditions may be 
vaccinated unless their condition constitutes a contraindication, such as 
pregnancy or severe immunodeficiency.
7. Measles, mumps, rubella (MMR) vaccination
•	 Adults born before 1957 are generally considered immune to measles and 
mumps. All adults born in 1957 or later should have documentation of 1 or 
more doses of MMR vaccine unless they have a medical contraindication to 
the vaccine or laboratory evidence of immunity to each of the three diseases. 
Documentation of provider-diagnosed disease is not considered acceptable 
evidence of immunity for measles, mumps, or rubella.
Measles component:
•	 A routine second dose of MMR vaccine, administered a minimum of 28 days 
after the first dose, is recommended for adults who:
 — are students in postsecondary educational institutions,
 — work in a health care facility, or
 — plan to travel internationally.
•	 Persons who received inactivated (killed) measles vaccine or measles vaccine of 
unknown type during 1963–1967 should be revaccinated with 2 doses of MMR 
vaccine.
Mumps component:
•	 A routine second dose of MMR vaccine, administered a minimum of 28 days 
after the first dose, is recommended for adults who:
 — are students in a postsecondary educational institution,
 — work in a health care facility, or
 — plan to travel internationally.
•	 Persons vaccinated before 1979 with either killed mumps vaccine or mumps 
vaccine of unknown type who are at high risk for mumps infection (e.g., persons 
who are working in a health care facility) should be considered for revaccination 
with 2 doses of MMR vaccine.
Rubella component:
•	 For women of childbearing age, regardless of birth year, rubella immunity 
should be determined. If there is no evidence of immunity, women who are not 
pregnant should be vaccinated. Pregnant women who do not have evidence 
of immunity should receive MMR vaccine upon completion or termination of 
pregnancy and before discharge from the health care facility.
Health care personnel born before 1957:
•	 For unvaccinated health care personnel born before 1957 who lack laboratory 
evidence of measles, mumps, and/or rubella immunity or laboratory 
confirmation of disease, health care facilities should consider vaccinating 
personnel with 2 doses of MMR vaccine at the appropriate interval for measles 
and mumps or 1 dose of MMR vaccine for rubella.
8. Pneumococcal (13-valent pneumococcal conjugate vaccine [PCV13] 
and 23-valent pneumococcal polysaccharide vaccine [PPSV23]) 
vaccination
•	 General information
 — When indicated, only a single dose of PCV13 is recommended for adults.
 — No additional dose of PPSV23 is indicated for adults vaccinated with 
PPSV23 at or after age 65 years.
 — When both PCV13 and PPSV23 are indicated, PCV13 should be 
administered first; PCV13 and PPSV23 should not be administered during 
the same visit.
 — When indicated, PCV13 and PPSV23 should be administered to adults 
whose pneumococcal vaccination history is incomplete or unknown.
•	 Adults aged 65 years or older who
 — Have not received PCV13 or PPSV23: Administer PCV13 followed by PPSV23 
in 6 to 12 months.
 — Have not received PCV13 but have received a dose of PPSV23 at age 65 
years or older: Administer PCV13 at least 1 year after the dose of PPSV23 
received at age 65 years or older.
Footnotes—Recommended Immunization Schedule for Adults Aged 19 Y ars or Older: Unite  States, 2015
(Continued on next page)
1. Additional information
•	 Additional guidance for the use of the vaccines described in this supplement is 
available at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
•	 Information on vaccination recommendations when vaccination status is 
unknown and other general immunization information can be found in the 
General Recommendations on Immunization at  
www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.
•	 Information on travel vaccine requirements and recommendations (e.g., for 
hepatitis A and B, meningococcal, and other vaccines) is available at  
wwwnc.cdc.gov/travel/destinations/list.
•	 Additional information and resources regarding vaccination of pregnant 
women can be found at www.cdc.gov/vaccines/adults/rec-vac/pregnant.html.
2. Influenza vaccination
•	 Annual vaccination against influenza is recommended for all persons aged 6 
months or older.
•	 Persons aged 6 months or older, including pregnant women and persons with 
hives-only allergy to eggs can receive the inactivated influenza vaccine (IIV). An 
age-appropriate IIV formulation should be used.
•	 Adults aged 18 years or older can receive the recombinant influenza vaccine 
(RIV) (FluBlok). RIV does not contain any egg protein and can be given to age-
appropriate persons with egg allergy of any severity.
•	 Healthy, nonpregnant persons aged 2 to 49 years without high-risk medical 
conditions can receive either intranasally administered live, attenuated 
influenza vaccine (LAIV) (FluMist) or IIV.
•	 Health care personnel who care for severely immunocompromised persons 
who require care in a protected environment should receive IIV or RIV; health 
care personnel who receive LAIV should avoid providing care for severely 
immunosuppressed persons for 7 days after vaccination.
•	 The intramuscularly or intradermally administered IIV are options for adults 
aged 18 through 64 years.
•	 Adults aged 65 years or older can receive the standard-dose IIV or the high-
dose IIV (Fluzone High-Dose).
•	 A list of currently available influenza vaccines can be found at  
www.cdc.gov/flu/protect/vaccine/vaccines.htm.
3. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination
•	 Administer 1 dose of Tdap vaccine to pregnant women during each pregnancy 
(preferably during 27 to 36 weeks’ gestation) regardless of interval since prior Td 
or Tdap vaccination.
•	 Persons aged 11 years or older who have not received Tdap vaccine or for 
whom vaccine status is unknown should receive a dose of Tdap followed by 
tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter. 
Tdap can be administered regardless of interval since the most recent tetanus 
or diphtheria-toxoid containing vaccine.
•	 Adults with an unknown or incomplete history of completing a 3-dose primary 
vaccination series with Td-containing vaccines should begin or complete a 
primary vaccination series including a Tdap dose.
•	 For unvaccinated adults, administer the first 2 doses at least 4 weeks apart and 
the third dose 6 to 12 months after the second.
•	 For incompletely vaccinated (i.e., less than 3 doses) adults, administer 
remaining doses.
•	 Refer to the ACIP statement for recommendations for administering Td/Tdap as 
prophylaxis in wound management (see footnote 1).
4. Varicella vaccinat
•	 All adults with t evidence of immunity to varicella (as defined below) should 
receive 2 doses of single-antigen varicella vaccine or a second dose if they have 
received only 1 dose.
•	 Vaccination should be emphasized for those who have close contact with 
persons at high risk for severe disease (e.g., health care personnel and 
family contacts of persons with immunocompromising conditions) or are at 
high risk for exposure or transmission (e.g., teachers; child care employees; 
residents and staff members of institutional settings, including correctional 
institutions; college students; military personnel; adolescents and adults living 
in households with children; nonpregnant women of childbearing age; and 
international travelers).
•	 Pregnant women should be assessed for evidence of varicella immunity. 
Women who do not have evidence of immunity should receive the first dose 
of varicella vaccine upon completion or termination of pregnancy and before 
discharge from the health care facility. The second dose should be administered 
4 to 8 weeks after the first dose.
•	 Evidence of immunity to varicella in adults includes any of the following:
 — documentation of 2 doses of varicella vaccine at least 4 weeks apart;
 — U.S.-born before 1980, except health care personnel and pregnant women;
 — history of varicella based on diagnosis or verification of varicella disease by 
a health care provider;
 — history of herpes zoster based on diagnosis or verification of herpes zoster 
disease by a health care provider; or
 — laboratory evidence of immunity or laboratory confirmation of disease.
5. Human papillomavirus (HPV) vaccination
•	 Two vaccines are licensed for use in females, bivalent HPV vaccine (HPV2) and 
quadrivalent HPV vaccine (HPV4), and one HPV vaccine for use in males (HPV4).
•	 For females, either HPV4 or HPV2 is recommended in a 3-dose series for routine 
vaccination at age 11 or 12 years and for those aged 13 through 26 years, if not 
previously vaccinated.
•	 For males, HPV4 is recommended in a 3-dose series for routine vaccination at 
age 11 or 12 years and for those aged 13 through 21 years, if not previously 
vaccinated. Males aged 22 through 26 years may be vaccinated.
•	 HPV4 is recommended for men who have sex with men through age 26 years 
for those who did not get any or all doses when they were younger.
•	 Vaccination is recommended for immunocompromised persons (including 
those with HIV infection) through age 26 years for those who did not get any or 
all doses when they were younger.
•	 A complete series for either HPV4 or HPV2 consists of 3 doses. The second dose 
should be administered 4 to 8 weeks (minimum interval of 4 weeks) after the 
first dose; the third dose should be administered 24 weeks after the first dose 
and 16 weeks after the second dose (minimum interval of at least 12 weeks).
•	 HPV vaccines are not recommended for use in pregnant women. However, 
pregnancy testing is not needed before vaccination. If a woman is found to 
be pregnant after initiating the vaccination series, no intervention is needed; 
the remainder of the 3-dose series should be delayed until completion or 
termination of pregnancy.
6. Zoster vaccination
•	 A single dose of zoster vaccine is recommended for adults aged 60 years 
or older regardless of whether they report a prior episode of herpes zoster. 
Although the vaccine is licensed by the U.S. Food and Drug Administration for 
use among and can be administered to persons aged 50 years or older, ACIP 
recommends that vaccination begin at age 60 years.
•	 Persons aged 60 years or older with chronic medical conditions may be 
vaccinated unless their condition constitutes a contraindication, such as 
pregnancy or severe immunodeficiency.
7. Measles, mumps, rubella (MMR) vaccination
•	 Adults born before 1957 are generally considered immune to measles and 
mumps. All adults born in 1957 or later should have documentation of 1 or 
more doses of MMR vaccine unless they have a medical contraindication to 
the vaccine or laboratory evidence of immunity to each of the three diseases. 
Documentation of provider-diagnosed disease is not considered acceptable 
evidence of immunity for measles, mumps, or rubella.
Measles component:
•	 A routine second dose of MMR vaccine, administered a minimum of 28 days 
after the first dose, is recommended for adults who:
 — are students in postsecondary educational institutions,
 — work in a health care facility, or
 — plan to travel internationally.
•	 Persons who received inactivated (killed) measles vaccine or measles vaccine of 
unknown type during 1963–1967 should be revaccinated with 2 doses of MMR 
vaccine.
Mu ps component:
•	 A routine second dose of MMR vaccine, administered  m nimum of 28 days 
after the first dose, is recommended for adults who:
 — are students in a posts condary educational instituti n,
 — work in a health care facility, or
 — plan to travel int rnationally.
•	 Persons vaccinated before 1979 with either killed mumps vaccine or mumps 
vaccine of u known type who are at high risk for mumps infection (e.g., persons 
who ar  working in a health care facility) should be considered for revaccination 
with 2 doses of MMR vaccine.
Rubella component:
•	 For women of childbearing age, regardless of birth year, rubella immunity 
should be determined. If there is no evidence of immunity, women who are not 
pregnant should be vaccinated. Pregnant women who do not have evidence 
of immunity should receive MMR vaccine upon completion or termination of 
pregnancy and before discharge from the health care facility.
Health care personnel born before 1957:
•	 Fo unvaccinated health care personnel born before 1957 who lack laboratory 
evidence of measles, mumps, and/ r rubella immunity or laboratory 
c nfi mation of disease, heal  car  facilities should consider vaccinating 
personnel with 2 doses of MMR vaccine at the approp iate interval for measles 
and mumps or 1 dose of MMR vaccine fo  rubella.
8. Pneumococcal (13-valent pneumococcal conjugate vaccine [PCV13] 
and 23-valent pneumococcal polysaccharide vaccine [PPSV23]) 
vaccination
•	 General information
 — When indicated, only a single dose of PCV13 is recommended for adults.
 — No additi nal dose of PPSV23 is indicat d for adults vaccin ted with
PPSV23 at or after age 65 years.
 — Wh n both PCV13 and PPSV23 are indicated, PCV13 shoul  be 
administered first; PCV13 and PPSV23 should not be administered during 
the s me visit.
 — When indicated, PCV13 and PPSV23 should be administered to adults 
whose p umococcal vaccination history is incomplete or unknown.
•	 Adults aged 65 years r older who
 — Have not receiv d PCV13 or PPSV23: Administer PCV13 followed by PPSV23 
in 6 to 12 months.
 — Have not received PCV13 but have received a dose of PPSV23 at age 65 
years or older: Administer PCV13 at least 1 year after the dose of PPSV23 
received at age 65 years or older.
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8. Pneumococcal v cci tion (continued)
 — Have not received PCV 3 but ave received 1 or more doses f PPSV23 
before age 65: Administer PCV13 at least 1 year after the most recent dose 
of PPSV23; administer a dose of PPSV23 6 to 12 months after PCV13, or as 
soon as possible if this time window has passed, and at least 5 years after 
the most recent dose of PPSV23.
 — Have received PCV13 but not PPSV23 before age 65 years: Administer 
PPSV23 6 to 12 months after PCV13 or as soon as possible if this time 
window has passed.
 — Have received PCV13 and 1 or more doses of PPSV23 before age 65 years: 
Administer PPSV23 6 to 12 months after PCV13, or as soon as possible if 
this time window has passed, and at least 5 years after the most recent 
dose of PPSV23.
•	 Adults aged 19 through 64 years with immunocompromising conditions or 
anatomical or functional asplenia (defined below) who 
 — Have not received PCV13 or PPSV23: Administer PCV13 followed by PPSV23 
at least 8 weeks after PCV13; administer a second dose of PPSV23 at least 5 
years after the first dose of PPSV23.
 — Have not received PCV13 but have received 1 dose of PPSV23: Administer 
PCV13 at least 1 year after the PPSV23; administer a second dose of PPSV23 
at l ast 8 weeks after PCV13 and at least 5 years after the first dose of 
PPSV23.
 — Have not rec ived PCV13 but have rece ved 2 doses of PPSV23: Administer 
PCV13 at least 1 year f er th most r cent dose f PPSV23.
 — Have received PCV13 but not PPSV23: Administer PPSV23 at east 8 weeks 
after PCV 3; administer a seco d dose of PPSV23 at least 5 years after the 
first dose of PPSV23.
 — Have received PCV13 and 1 dose of PPSV23: Administer a second dose of 
PPSV23 at least 5 years after the first dose of PPSV23.
•	 Adults aged 19 through 64 years with cerebrospinal fluid leaks or cochlear 
implants: Administer PCV13 followed by PPSV23 at least 8 weeks after PCV13.
•	 Adults aged 19 through 64 years with chronic heart disease (including 
congestive heart failure and cardiomyopathies, excluding hypertension), 
chronic lung disease (including chronic obstructive lung disease, emphysema, 
and asthma), chronic liver disease (including cirrhosis), alcoholism, or diabetes 
mellitus: Administer PPSV23.
•	 Adults aged 19 through 64 years who smoke cigarettes or reside in nursing 
home or long-term care facilities: Administer PPSV23.
•	 Routine pneumococcal vaccination is not recommended for American Indian/
Alaska Native or other adults unless they have the indications as above; 
however, public health authorities may consider recommending the use of 
pneumococcal vaccines for American Indians/Alaska Natives or other adults 
who live in areas with increased risk for invasive pneumococcal disease.
•	 Immunocompromising conditions that are indications for pneumococcal 
vaccination are: Congenital or acquired immunodeficiency (including B- or 
T-lymphocyte deficiency, complement deficiencies, and phagocytic disorders 
excluding chronic granulomatous disease), HIV infection, chronic renal failure, 
nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized 
malignancy, multiple myeloma, solid organ transplant, and iatrogenic 
immunosuppression (including long-term systemic corticosteroids and 
radiation therapy).
•	 Anatomical or functional asplenia that are indications for pneumococcal 
vaccination are: Sickle cell disease and other hemoglobinopathies, congenital 
or acquired asplenia, splenic dysfunction, and splenectomy. Administer 
pneumococcal vaccines at least 2 weeks before immunosuppressive therapy 
or an elective splenectomy, and as soon as possible to adults who are newly 
diagnosed with asymptomatic or symptomatic HIV infection.
9. Meningococcal vaccination
•	 Administer 2 doses of quadrivalent meningococcal conjugate vaccine 
(MenACWY [Menactra, Menveo]) at least 2 months apart to adults of all ages 
with anatomical or functional asplenia or persistent complement component 
deficiencies. HIV infection is not an indication for routine vaccination with 
MenACWY. If an HIV-infected person of any age is vaccinated, 2 doses of 
MenACWY should be administered at least 2 months apart.
•	 Administer a single dose of meningococcal vaccine to microbiologists routinely 
exposed to isolates of Neisseria meningitidis, military recruits, persons at risk 
during an outbreak attributable to a vaccine serogroup, and persons who travel 
to or live in countries in which meningococcal disease is hyperendemic or 
epidemic.
•	 First-year college students up through age 21 years who are living in residence 
halls should be vaccinated if they have not received a dose on or after their 16th 
birthday.
•	 MenACWY is preferred for adults with any of the preceding indications who 
are aged 55 years or younger as well as for adults aged 56 years or older who 
a) were vaccinated previously with MenACWY and are recommended for 
revaccination, or b) for whom multiple doses are anticipated. Meningococcal 
polysaccharide vaccine (MPSV4 [Menomune]) is preferred for adults aged 56 
years or older who have not received MenACWY previously and who require a 
single dose only (e.g., travelers).
•	 Revaccination with MenACWY every 5 years is recommended for adults 
previously vaccinated with MenACWY or MPSV4 who remain at increased risk 
for infection (e.g., adults with anatomical or functional asplenia, persistent 
complement component deficiencies, or microbiologists).
10. Hepatitis A vaccination
•	 Vaccinate any person seeking protection from hepatitis A virus (HAV) infection 
and persons with any of the following indications:
 — men who have sex with men and persons who use injection or 
noninjection illicit drugs;
 — persons working with HAV-infected primates or with HAV in a research 
laboratory setting;
 — persons with chronic liver disease and persons who receive clotting factor 
concentrates;
 — persons traveling to or working in countries that have high or intermediate 
endemicity of hepatitis A; and
 — unvaccinated persons who anticipate close personal contact (e.g., 
household or regular babysitting) with an international adoptee during 
the first 60 days after arrival in the United States from a country with high 
or intermediate endemicity. (See footnote 1 for more information on travel 
recommendations.) The first dose of the 2-dose hepatitis A vaccine series 
should be administered as soon as adoption is planned, ideally 2 or more 
weeks before the arrival of the adoptee.
•	 Single-antigen vaccine formulations should be administered in a 2-dose 
schedule at either 0 and 6 to 12 months (Havrix), or 0 and 6 to 18 months 
(Vaqta). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, 
administer 3 doses at 0, 1, and 6 months; alternatively, a 4-dose schedule may 
be used, administered on days 0, 7, and 21 to 30 followed by a booster dose at 
month 12.
11. Hepatitis B vaccination
•	 Vaccinate persons with any of the following indications and any person seeking 
protection from hepatitis B virus (HBV) infection:
 — sexually active persons who are not in a long-term, mutually monogamous 
relationship (e.g., persons with more than 1 sex partner during the 
previous 6 months); persons seeking evaluation or treatment for a sexually 
transmitted disease (STD); current or recent injection drug users; and men 
who have sex with men;
 — health care personnel and public safety workers who are potentially 
exposed to blood or other infectious body fluids;
 — persons with diabetes who are younger than age 60 years as soon as 
feasible after diagnosis; persons with diabetes who are age 60 years or 
older at the discretion of the treating clinician based on the likelihood of 
acquiring HBV infection, including the risk posed by an increased need 
for assisted blood glucose monitoring in long-term care facilities, the 
likelihood of experiencing chronic sequelae if infected with HBV, and the 
likelihood of immune response to vaccination;
 — persons with end-stage renal disease, including patients receiving 
hemodialysis, persons with HIV infection, and persons with chronic liver 
disease;
 — household contacts and sex partners of hepatitis B surface antigen–
positive persons, clients and staff members of institutions for persons with 
developmental disabilities, and international travelers to countries with 
high or intermediate prevalence of chronic HBV infection; and
 — all adults in the following settings: STD treatment facilities, HIV testing 
and treatment facilities, facilities providing drug abuse treatment and 
prevention services, health care settings targeting services to injection 
drug users or men who have sex with men, correctional facilities, end-stage 
renal disease programs and facilities for chronic hemodialysis patients, 
and institutions and nonresidential day care facilities for persons with 
developmental disabilities.
•	 Administer missing doses to complete a 3-dose series of hepatitis B vaccine to 
those persons not vaccinated or not completely vaccinated. The second dose 
should be administered 1 month after the first dose; the third dose should be 
given at least 2 months after the second dose (and at least 4 months after the 
first dose). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, 
give 3 doses at 0, 1, and 6 months; alternatively, a 4-dose Twinrix schedule, 
administered on days 0, 7, and 21 to 30 followed by a booster dose at month 12 
may be used.
•	 Adult patients receiving hemodialysis or with other immunocompromising 
conditions should receive 1 dose of 40 mcg/mL (Recombivax HB) administered 
on a 3-dose schedule at 0, 1, and 6 months or 2 doses of 20 mcg/mL (Engerix-B) 
administered simultaneously on a 4-dose schedule at 0, 1, 2, and 6 months.
12. Haemophilus influenzae type b (Hib) vaccination
•	 One dose of Hib vaccine should be administered to persons who have 
anatomical or functional asplenia or sickle cell disease or are undergoing 
elective splenectomy if they have not previously received Hib vaccine. Hib 
vaccination 14 or more days before splenectomy is suggested.
•	 Recipients of a hematopoietic stem cell transplant (HSCT) should be vaccinated 
with a 3-dose regimen 6 to 12 months after a successful transplant, regardless 
of vaccination history; at least 4 weeks should separate doses.
•	 Hib vaccine is not recommended for adults with HIV infection since their risk for 
Hib infection is low.
13. Immunocompromising conditions
•	 Inactivated vaccines generally are acceptable (e.g., pneumococcal, 
meningococcal, and inactivated influenza vaccine) and live vaccines generally 
are avoided in persons with immune deficiencies or immunocompromising 
conditions. Information on specific conditions is available at  
www.cdc.gov/vaccines/hcp/acip-recs/index.html.
Footnotes—Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2015
8. Pneumococcal vaccination (continued)
 — Have not received PCV13 but have received 1 or ore doses of PPSV23 
before age 65: Administer PCV13 at least 1 year after the most recent dose 
of PPSV23; administer a dose of PPSV23 6 to 12 months after PCV13, or as 
soon as possible if this time window has passed, and at least 5 years after 
the most recent dose of PPSV23.
 — Have received PCV13 but not PPSV23 before age 65 years: Administer 
PPSV23 6 to 12 months after PCV13 or as soon as possible if this time 
window has passed.
 — Have received PCV13 and 1 or more doses of PPSV23 before age 65 years: 
Administer PPSV23 6 to 12 months after PCV13, or as soon as possible if 
this time window has pass d, a d at least 5 years after the ost recent 
dose of PPSV23.
•	 Adults aged 19 through 64 years with immun compromisi g c nditions or 
anatomical or functional aspleni  (defined below) who 
 — Hav  ot r ceived PCV13 or PPSV23: Administ r PCV13 followed by PPSV23 
at least 8 weeks after PCV13; administer a second dose of PPSV23 at least 5 
years after the first dose of PPSV23.
 — Have not received PCV13 but have received 1 dose of PPSV23: Administer 
PCV13 at least 1 year after the PPSV23; administer a second dose of PPSV23 
at least 8 weeks after PCV13 and at least 5 years after the first dose of 
PPSV23.
 — Have not received PCV13 but have received 2 doses of PPSV23: Administer 
PCV13 at least 1 year aft r the m st recent dose of PPSV23.
 — H v  receiv d PCV13 but not PPSV23: Administer PPSV23 at least 8 weeks 
after PCV13; administer a second dose of PPSV23 at least 5 years after the 
first dose of PPSV23.
 — Have re eived PCV13 a d 1 PSV23: Administ r a sec nd ose of 
PPSV23 at east 5 years after the first dose of PPSV23.
•	 Adults aged 19 throu h 4 rs wit  cerebrospinal fluid le ks or cochlear 
implants: Administer PCV13 followed by PPSV23 at least 8 weeks after PCV13.
•	 Adults aged 19 through 64 years with chronic hear disease (including 
conges iv  heart fa lure and cardiomyopathies, exclud ng hypert nsion), 
chronic lung disease (including chronic bstructive lung dis ase, emphysema, 
and asthma), chr ni  liver disease (including cirrh sis), alcoholism, or diabetes 
mellitus: Administer PPSV23.
•	 Adults aged 19 through 64 years who smoke cigarettes or reside in nursing 
home r long-term care facilities: Administer PPSV23.
•	 Routine pneumococcal vaccination is not recommended for American Indian/
Alaska Native or other adults unless they have the indications as above; 
however, public health authorities may consider recommending the use of 
pneumococcal vaccines for American Indians/Alaska Natives or other adults 
who live in areas with increased risk for invasive pneumococcal disease.
•	 Immunocompromising conditions that are indications for pneumococcal 
vaccination are: Congenital or acquired immunodeficiency (including B- or 
T-lymphocyte deficiency, complement deficiencies, and phagocytic disorders 
excluding chronic granulomatous disease), HIV infection, chronic renal failure, 
nephrotic syndro e, leukemia, lymphoma, Hodgkin disease, generalized 
malignancy, multiple myeloma, solid organ transplant, and iatrogenic 
immunosuppression (including long-term systemic corticosteroids and 
radiation therapy).
•	 Anatomical or functional asplenia that are indications for pneumococcal 
vaccination are: Sickle cell disease and other hemoglobinopathies, congenital 
or acquired asplenia, splenic dysfunction, and splenectomy. Administer 
pneu ococcal vaccines at least 2 weeks before immunosuppressive therapy 
or an elective splenectomy, and as soon as possible to adults who are newly 
diagnosed with asymptomatic or symptomatic HIV infection.
9. Meningococcal vaccination
•	 Administer 2 doses of quadrivalent meningococcal conjugate vaccine 
(MenACWY [Menactra, Menveo]) at least 2 onths apart to adults of all ages 
with anatomical or functional asplenia or persistent complement component 
deficiencies. HIV infection is not an indication for routine vaccination with 
MenACWY. If an HIV-infected person of any age is vaccinated, 2 doses of 
MenACWY should be administered at least 2 months apart.
•	 Administer a single dose of meningococcal vaccine to microbiologists routinely 
exposed to isolates of Neisseria meningitidis, military recruits, persons at risk 
during an outbreak attributable to a vaccine serogroup, and persons who travel 
to or live in countries in which meningococcal disease is hyperendemic or 
epidemic.
•	 First-year college students up through age 21 years who are living in residence 
halls should be vaccinated if they have not received a dose on or after their 16th 
birthday.
•	 MenACWY is preferred for adults with any of the preceding indications who 
are aged 55 years or younger as well as for adults aged 56 years or older who 
a) were vaccinated previously with MenACWY and are recommended for 
revaccination, or b) for whom multiple doses are anticipated. Meningococcal 
polysaccharide vaccine (MPSV4 [Menomune]) is preferred for adults aged 56 
years or older who have not received MenACWY previously and who require a 
single dose only (e.g., travelers).
•	 Revaccination with MenACWY every 5 years is recommended for adults 
previously vaccinated with MenACWY or MPSV4 who remain at increased risk 
for infection (e.g., adults with anatomical or functional asplenia, persistent 
complement component deficiencies, or microbiologists).
10. Hepatitis A vaccination
•	 Vaccinate any person seeking protection from hepatitis A virus (HAV) infection 
and persons with any of the following indications:
 — men who have sex with men and persons who use injection or 
noninjection illicit drugs;
 — persons working with HAV-infected primates or with HAV in a research 
laboratory setting;
 — persons with chronic liver disease and persons who receive clotting factor 
concentrates;
 — persons traveling to or working in countries that have high or intermediate 
endemicity of hepatitis A; and
 — unvaccinated persons who anticipate close personal contact (e.g., 
household or regular babysitting) with an international adoptee during 
the first 60 days after arrival in the United States from a country with high 
or intermediate endemicity. (See footnote 1 for more information on travel 
recommendations.) The first dose of the 2-dose hepatitis A vaccine series 
should be administered as soon as adoption is planned, ideally 2 or more 
weeks before the arrival of the adoptee.
•	 Single-antigen vaccine formulations should be administered in a 2-dose 
schedule at either 0 and 6 to 12 months (Havrix), or 0 and 6 to 18 months 
(Vaqta). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, 
administer 3 doses at 0, 1, and 6 months; alternatively, a 4-dose schedule may 
be used, administered on days 0, 7, and 21 to 30 followed by a booster dose at 
month 12.
11. Hepatitis B vaccination
•	 Vaccinate persons with any of the following indications and any person seeking 
protection from hepatitis B virus (HBV) infection:
 — sexually active persons who are not in a long-term, mutually monogamous 
relationship (e.g., persons with more than 1 sex partner during the 
previous 6 months); persons seeking evaluation or treatment for a sexually 
transmitted disease (STD); current or recent injection drug users; and men 
who have sex with men;
 — health care personnel and public safety workers who are potentially 
exposed to blood or other infectious body fluids;
 — persons with diabetes who are younger than age 60 years as soon as 
feasible after diagnosis; persons with diabetes who are age 60 years or 
older at the discretion of the treating clinician based on the likelihood of 
acquiring HBV infection, including the risk posed by an increased need 
for assisted blood glucose monitoring in long-term care facilities, the 
likelihood of experiencing chronic sequelae if infected with HBV, and the 
likelihood of immune response to vaccination;
 — persons with end-stage renal disease, including patients receiving 
hemodialysis, persons with HIV infection, and persons with chronic liver 
disease;
 — household contacts and sex partners of hepatitis B surface antigen–
positive persons, clients and staff members of institutions for persons with 
developmental disabilities, and international travelers to countries with 
high or intermediate prevalence of chronic HBV infection; and
 — all adults in the following settings: STD treatment facilities, HIV testing 
and treatment facilities, facilities providing drug abuse treatment and 
prevention services, health care settings targeting services to injection 
drug users or men who have sex with men, correctional facilities, end-stage 
renal disease programs and facilities for chronic hemodialysis patients, 
and institutions and nonresidential day care facilities for persons with 
developmental disabilities.
•	 Administer missing doses to complete a 3-dose series of hepatitis B vaccine to 
those persons not vaccinated or not completely vaccinated. The second dose 
should be administered 1 month after the first dose; the third dose should be 
given at least 2 months after the second dose (and at least 4 months after the 
first dose). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, 
give 3 doses at 0, 1, and 6 months; alternatively, a 4-dose Twinrix schedule, 
administered on days 0, 7, and 21 to 30 followed by a booster dose at month 12 
may be used.
•	 Adult patients receiving hemodialysis or with other immunocompromising 
conditions should receive 1 dose of 40 mcg/mL (Recombivax HB) administered 
on a 3-dose schedule at 0, 1, and 6 months or 2 doses of 20 mcg/mL (Engerix-B) 
administered simultaneously on a 4-dose schedule at 0, 1, 2, and 6 months.
12. Haemophilus influenzae type b (Hib) vaccination
•	 One dose of Hib vaccine should be administered to persons who have 
anatomical or functional asplenia or sickle cell disease or are undergoing 
elective splenectomy if they have not previously received Hib vaccine. Hib 
vaccination 14 or more days before splenectomy is suggested.
•	 Recipients of a hematopoietic stem cell transplant (HSCT) should be vaccinated 
with a 3-dose regimen 6 to 12 months after a successful transplant, regardless 
of vaccination history; at least 4 weeks should separate doses.
•	 Hib vaccine is not recommended for adults with HIV infection since their risk for 
Hib infection is low.
13. Immunocompromising conditions
•	 Inactivated vaccines generally are acceptable (e.g., pneumococcal, 
meningococcal, and inactivated influenza vaccine) and live vaccines generally 
are avoided in persons with immune deficiencies or immunocompromising 
conditions. Information on specific conditions is available at  
www.cdc.gov/vaccines/hcp/acip-recs/index.html.
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